Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.6M
-
Number of holders
-
185
-
Total 13F shares, excl. options
-
84.5M
-
Shares change
-
+8.35M
-
Total reported value, excl. options
-
$1.48B
-
Value change
-
+$150M
-
Put/Call ratio
-
0.34
-
Number of buys
-
107
-
Number of sells
-
-69
-
Price
-
$17.45
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q2 2025
218 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 185 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 84.5M shares
of 98.6M outstanding shares and own 85.75% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (10.9M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (9.72M shares), ORBIMED ADVISORS LLC (8.29M shares), BlackRock, Inc. (4.42M shares), SR One Capital Management, LP (4.01M shares), ALLIANCEBERNSTEIN L.P. (3.83M shares), VANGUARD GROUP INC (3.26M shares), CITADEL ADVISORS LLC (2.24M shares), STATE STREET CORP (2.19M shares), and FRANKLIN RESOURCES INC (1.83M shares).
This table shows the top 185 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.